关键词: 二氢杨梅素, 阿霉素, 荷瘤小鼠, 抗肿瘤作用

Abstract:

In order to explore the synergy and attenuation effects of dihydromyricetin ( DMY) on the tumor-bearing mice affected by breast cancer treated with adriamycin ( ADM),a model of transplanted 4T1 was established in the female Balb /C mice. Then,the effects of DMY alone,ADM alone and ADM combined with DMY on the mass of the transplanted tumor,the lung metastatic loci,the cardiotoxicity and the hepatotoxicity were studied. The results
show that,as compared with the control group ( physiological saline) ,100 mg /( kg·d) DMY has no significant effect on the tumor mass as well as the creatine kinase,the alanine transaminase and the aspartate aminotransferase ( AST) activities,but significantly reduces the serum lactate dehydrogenase ( LDH) activity ( P ＜ 0. 05) and the lung metastatic loci ( P ＜ 0. 01) ,that 2 mg /( kg·d) ADM significantly decreases the tumor mass ( P ＜ 0. 05) and the lung metastatic loci ( P ＜ 0. 01) but significantly increases the LDH and AST activities ( P＜0. 05) ,and that 2mg /( kg·d) ADM combined with 100mg /( kg·d) DMY brings about better antitumor effect,that is,not only the tumor mass and the lung metastatic loci but also the increments of the LDH and AST activities induced by ADMalone decrease,with a significance level of P ＜ 0. 01 for the former. The above-mentioned details indicate that ADM can significantly inhibit the growth and lung metastasis of transplanted 4T1 in tumor-bearing mice,although it may result in cardiotoxicity and hepatotoxicity to a certain degree,and that DMY can enhance the antitumor effects of ADM and attenuate adriamycin-induced cardiotoxicity and hepatotoxicity.

Key words: dihydromyricetin, adriamycin, tumor-bearing mice, antitumor effect